Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tipranavir

FDA-approved product (capsule, oral), marketed as Aptivus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tipranavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tipranavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tipranavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

    NCT02226978 · start 2007-02

    Registered record
    Registry ID
    NCT02226978
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Valaciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-02
    Completion
    Not recorded
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Valaciclovir
    PhasePhase 1
    Registry statusCompleted

  • Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

    NCT00531206 · start 2006-08

    Registered record
    Registry ID
    NCT00531206
    Conditions
    HIV Infections
    Interventions
    Tipranavir; Ritonavir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-08
    Completion
    Not recorded
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir; Ritonavir
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

    NCT02229760 · start 2006-08

    Registered record
    Registry ID
    NCT02229760
    Conditions
    HIV Infections
    Interventions
    Tipranavir capsules; Ritonavir capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2006-08
    Completion
    Not recorded
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir capsules; Ritonavir capsules
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

    NCT00352066 · start 2006-07

    Registered record
    Registry ID
    NCT00352066
    Conditions
    HIV Infection
    Interventions
    apricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionapricitabine
    PhasePhase 1
    Registry statusCompleted

  • Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

    NCT02226991 · start 2006-04

    Registered record
    Registry ID
    NCT02226991
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-04
    Completion
    Not recorded
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

    NCT00294372 · start 2006-02

    Registered record
    Registry ID
    NCT00294372
    Conditions
    HIV Infections
    Interventions
    BILR 355 BS; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-02
    Completion
    Not recorded
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionBILR 355 BS; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

    NCT02259855 · start 2006-01-01

    Registered record
    Registry ID
    NCT02259855
    Conditions
    Hepatic Insufficiency
    Interventions
    Tipranavir; Ritonavir; Pegylated interferon; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01-01
    Completion
    Not recorded
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    InterventionTipranavir; Ritonavir; Pegylated interferon; Ribavirin
    PhasePhase 1
    Registry statusCompleted

  • Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

    NCT02248883 · start 2005-12

    Registered record
    Registry ID
    NCT02248883
    Conditions
    Healthy
    Interventions
    TPV low; Placebo; Moxifloxacin; TPV high; RTV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTPV low; Placebo; Moxifloxacin; TPV high +1 more
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

    NCT02253862 · start 2005-12

    Registered record
    Registry ID
    NCT02253862
    Conditions
    Healthy
    Interventions
    Tadalafil; Tipranavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTadalafil; Tipranavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers

    NCT02253849 · start 2005-11

    Registered record
    Registry ID
    NCT02253849
    Conditions
    Healthy
    Interventions
    Carbamazepine; Tipranavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    Not recorded
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCarbamazepine; Tipranavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

    NCT02257021 · start 2005-02

    Registered record
    Registry ID
    NCT02257021
    Conditions
    Healthy
    Interventions
    BILR 355 BS; Tipranavir; Low dose of ritonavir; High dose of ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-02
    Completion
    Not recorded
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBILR 355 BS; Tipranavir; Low dose of ritonavir; High dose of ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

    NCT02253836 · start 2005-01

    Registered record
    Registry ID
    NCT02253836
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-01
    Completion
    Not recorded
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Atazanavir
    PhasePhase 1
    Registry statusCompleted

  • Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

    NCT00097799 · start 2004-12

    Registered record
    Registry ID
    NCT00097799
    Conditions
    HIV Infections
    Interventions
    Tipranavir; Ritonavir
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    2004-12
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir; Ritonavir
    PhaseNot recorded
    Registry statusApproved for marketing

  • Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

    NCT00144287 · start 2004-05

    Registered record
    Registry ID
    NCT00144287
    Conditions
    HIV Infections
    Interventions
    Tipranavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-05
    Completion
    2006-04
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir/Ritonavir
    PhasePhase 3
    Registry statusCompleted

  • A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

    NCT00144105 · start 2004-02

    Registered record
    Registry ID
    NCT00144105
    Conditions
    HIV Infections
    Interventions
    TPV500mg/RTV200mgBID; TPV500mg/RTV100mgBID; LPV400mg/RTV100mgBID
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-02
    Completion
    Not recorded
    Enrolment
    562

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTPV500mg/RTV200mgBID; TPV500mg/RTV100mgBID; LPV400mg/RTV100mgBID
    PhasePhase 2
    Registry statusTerminated